Diagnostic Testing of Common Sexually Transmitted Infections
Customize your policy alerts
Sign up for Blue Cross Blue Shield - New Mexico Policy RPLAB051 alerts
Get alerted when Policy RPLAB051 changes without checking for updates manually.
Monitor payer policy activity
This reimbursement policy governs coverage and reimbursement criteria for diagnostic testing of common STIs (C. trachomatis, N. gonorrhoeae, T. pallidum, T. vaginalis and select others) for Blue Cross Blue Shield of New Mexico providers and members.
Added prenatal STI screening previously addressed on CPCPLAB014 Prenatal Testing (Non genetic), resulting in addition of #2.a, #5.e, #6.a, and #10.a.
For individuals currently or previously diagnosed with syphilis, treponemal Ig testing is not reimbursable.
For symptomatic individuals, testing for Mycoplasma genitalium using NAAT may be reimbursable; for asymptomatic individuals screening for M. genitalium using NAAT is not reimbursable.
Trichomonas vaginalis added to #24 as not reimbursable (direct probe/quantitative NAAT section); added specific CPT/other codes.
Qualitative NAAT phrasing added to several items for clarity (e.g., #4, #7, #12, #15).
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.